Welcome to the e-CCO Library Archive!

Filter:
P392. Outcomes after elective withdrawal of anti-TNF therapy in Crohn's disease: a multicentre study
Authors:

S. Sebastian1, K. Robinson2, L. Warren3, A. Marsh2, A. Wright2, F. Majeed3, H. Tsai1, A. Brooks2, M.E. McAlindon2, P.J. Hamlin3, A. Lobo2, 1Hull & East Yorkshire NHS Trust, Hull & York Medical School, United Kingdom, 2Sheffield Teaching Hospitals NHS Trust, United Kingdom, 3Leeds Teaching Hospitals NHS Trust, United Kingdom

P392

Low uptake of cervical screening in immunosuppressed patients with Inflammatory Bowel Disease at a district general hospital

Authors:

K. Wade*, H. Johnson, H. Dewhurst, S. Weaver, S. McLaughlin

Royal Bournemouth Hospital, Department of Gastroenterology, Bournemouth, United Kingdom

P393.

Patient-reported symptom measures differ in their association with mucosal healing in adults with moderately to severely active ulcerative colitis: Results from ULTRA 1 and 2

Authors:

J.-F. Colombel1, W.J. Sandborn2, W. Reinisch3, A.M. Robinson4, W. Wang4, B. Huang4, A. Lazar5, R. Thakkar4, 1Icahn School of Medicine at Mount Sinai, Division of Gastroenterology, New York, United States, 2University of California, San Diego, Division of Gastroenterology, La Jolla, United States, 3McMaster University, Department of Medicine, Hamilton, Canada, 4AbbVie Inc, GPRD, North Chicago, United States, 5AbbVie Deutschland GmbH & Co, KG, GPRD, Ludwigshafen, Germany

P393. Combination of surgical therapy and local injections of adalimumab in treatment of complex perianal Crohn's disease
P393. Occurrence of stricturing and penetrating complications is diminished in Crohn's disease patients treated by immunomodulatory and/or anti-TNF therapy within the first two years of disease duration when corrected for diagnostic delay
Authors:

E. Safroneeva1, S. Vavricka2, N. Fournier3, G. Rogler2, A. Straumann4, A. Schoepfer5, 1University of Bern, Institute of Social and Preventive Medicine, Bern, Switzerland, 2University Hospital Zurich, Gastroenterology and Hepatology, Zurich, Switzerland, 3University of Lausanne, Institute of Social and Preventive Medicine, Lausanne, Switzerland, 4University Hospital Basel, Gastroenterology and Hepatology, Switzerland, 5University Hospital Lausanne / CHUV, Gastroenterology and Hepatology, Lausanne, Switzerland

P393

Measles, Mumps and Rubella Seronegativity Rates in IBD Patients Commencing Biologic Therapy

Authors:

R. Stack*1, 2, U. Kennedy1, D. Schmidt1, 2, M. Walshe1, 2, F. MacCarthy1, 2, N. Mahmud1, 2, S. McKiernan1, 2, D. Kevans1, 2

1St James's Hospital, Gastroenterology, Dublin, Ireland, 2Trinity College Dublin, School of Medicine, Dublin, Ireland

P394.

Pooled clinical trial analysis of MMX mesalazine safety: Focus on 4.8 g/d dose long-term exposure

Authors:

S. Da Silva Sanchez1, M. Palmen2, P. Streck3, S. Inglis2, 1Shire, Medical Affairs, Brussels, Belgium, 2Shire, Clinical Development, Basingstoke, United Kingdom, 3Shire, Clinical Research & Development, Wayne, PA, United States

P394. Predictors of endoscopic recurrence in a cohort of Crohn's disease patients after intestinal resection
P394. Rate of and response to dose escalation in patients treated with adalimumab for moderately to severely active ulcerative colitis: subanalysis of ULTRA 2
Authors:

D. Wolf1, G. D'Haens2, W. Sandborn3, J.-F. Colombel4, G. Van Assche5, A. Lazar6, Q. Zhou7, A. Robinson7, J. Chao7, R. Thakkar7, 1Atlanta Gastroenterology Associates, Atlanta, United States, 2Academic Medical Center, Amsterdam, Netherlands, 3University of California San Diego, La Jolla, United States, 4Centre Hospitalier Universitaire de Lille, Lille, France, 5University of Toronto, Toronto, Canada, 6AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany, 7Abbott Laboratories, Abbott Park, United States

P394

Prevalence of malnutrition in patients with Inflammatory Bowel Disease - a Romanian National Register based study

Authors:

M. Ispas*1, A. Lupu1, L. Gheorghe1, D. Dobru2, A. Tantau3, A. Goldis4, M. Ilie5, C. Gheorghe1, M. Ciocirlan1, C. Cijevschi6, C. Mihai6, R. Iacob1, M. Diculescu1

1Fundeni Clinical Institute, Gastroenterology, Bucharest, Romania, 2Municipal Hospital Targu Mures, Gastroenterology, Targu Mures, Romania, 33rd Medical Clinic Cluj-Napoca, Gastroenterology, Cluj-Napoca, Romania, 4University of Medicine ‘Victor Babes’, Clinic of Gastroenterology, Timisoara, Romania, 5Floreasca Emergency Hospital, Gastroenterology, Bucharest, Romania, 6Gastroenterology and Hepatology Institute , Gastroenterology, Iasi, Romania

P395.

Perianal Crohn's disease – Experience of a tertiary referral center

Authors:

S. Fernandes, P. Sousa, M. Moura, L. Correia, A. Rita Gonçalves, P. Moura Santos, A. Valente, C. Baldaia, J. Velosa, Centro Hospitalar Lisboa Norte, Gastrenterology, Lisbon, Portugal

P395. Long-term results of surgery for ileocecal Crohn's disease
P395. Re-induction regimen in Crohn's disease adalimumab failure or disease relapse after a first adalimumab course. A single centre experience
Authors:

C. Praticò1, P. Gionchetti1, G. Spuri Fornarini1, A. Calafiore1, M. Campieri1, C. Calabrese1, F. Rizzello1, 1Bologna, Clinical Medicine, Bologna, Italy

P395

Therapeutic adherence in patients with inflammatory bowel disease.

Authors:

C. Azucena*, B. Nallely, Y.-F. Jesus

IBD Clinic, Instituto Nacional de Ciencias Medicas y Nutricion, Gastroenterology, Mexico, Mexico

P396.

Outcomes of surgical treatment of entero-urinary fistulas in Crohn's disease

Authors:

I. Fernández-Blanco1, C. Taxonera2,3, G. Bastida4, V. García-Sánchez5, M. Gómez-García6, I. Marín-Jiménez7, E. Iglesias5, J.P. Gisbert8,9, M. Barreiro-de Acosta10, F. Bermejo11, M.J. Casanova8,9, C. Saro12, P. López-Serrano13, R. Plaza14, A. Algaba11, D. Olivares2,3, J.L. Mendoza2,3, 1Hospital Moncloa, Gastrointestinal Surgery, Madrid, Spain, 2H Clinico San Carlos, IdISSC, Madrid, Spain, 3H Clinico San Carlos, IBD Unit, Madrid, Spain, 4H La Fe, Service of Gastroenterology, Valencia, Spain, 5H Reina Sofía, Service of Gastroenterology, Córdoba, Spain, 6H Virgen de las Nieves, Service of Gastroenterology, Granada, Spain, 7H Gregorio Marañón, Service of Gastroenterology, Madrid, Spain, 8IP, CIBERehd, Madrid, Spain, 9H La Princesa, Gastroenterology Unit, Madrid, Spain, 10H Clinico de Santiago, Service of Gastroenterology, Santiago de Compostela, Spain, 11H Fuenlabrada, Service of Gastroenterology, Madrid, Spain, 12H de Cabueñes, Service of Gastroenterology, Gijón, Spain, 13H Alcorcón, Service of Gastroenterology, Madrid, Spain, 14H Infanta Leonor, Service of Gastroenterology, Madrid, Spain

P396. Predictive factors of disease relapse following thiopurine withdrawal for sustained clinical remission of IBD
P396. Rates of infections in patients with inflammatory bowel disease receiving biological drugs
Authors:

V. Rodil1, M.L. De Castro2, V. Hernández3, J.R. Pineda3, S. Pereira3, J. Martínez Cadilla3, P. Estévez3, L. Cid3, D. Martínez-Ares3, L. Sanromán3, V. Del Campo4, J.I. Rodríguez Prada3, 1Universitary Hospital, Internal Medicine, Vigo, Spain, 2Universitary Hospital, Gastroenterology, Vigo, Spain, 3Universitary Hospital, Gastroenterology, Vigo, Spain, 4Universitary Hospital, Epidemiology, Vigo, Spain

P396

Adalimumab induction therapy achieves clinical remission and response in chinese patients with Crohn's Disease

Authors:

K.-C. Wu*1, Z.H. Ran2, X. Gao3, M. Chen4, J. Zhong5, J.-Q. Sheng6, M.A. Kamm7, 8, S. Travis9, A.M. Robinson10, K. Wallace10, M. Shapiro10, Y. Li10, R.B. Thakkar10

1Xijing Hospital of the Fourth Military Medical University, Gastroenterology, Xi’an, China, 2Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China, 3The Sixth Affiliated Hospital of Sun Yat-sen University, Gastroenterology, Guangzhou, China, 4The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China, 5Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China, 6The Military General Hospital of Beijing, PLA, Gastroenterology, Beijing, China, 7St. Vincent’s Hospital, Gastroenterology, Melbourne, Australia, 8The University of Melbourne, Gastroenterology, Parkville, Australia, 9Translational Gastroenterology Unit, Gastroenterology, Oxford, United Kingdom, 10AbbVie Inc., Global Pharmaceutical Research & Development, North Chicago, United States

P397.

Outcomes after dose escalation of infliximab in Japanese patients with Crohn's disease

Authors:

M. Sako, T. Kawaguchi, A. Hirayama, G. Fukushi, K. Hayama, T. Fujiwara, N. Yoshimura, M. Takazoe, Social Insurance Central Hospital, Centre for Inflammatory Bowel Disease, Tokyo, Japan

P397. Feasibility and safety of accelerated versus standard infliximab (IFX) infusion-protocols in inflammatory bowel disease (IBD) patients: A retrospective analysis